GlassScriptPhysician profile
James A Patterson
NPI 1396788493
$2,553.08
in general payments reported to CMS, 2019-2025
22 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $253 · 2021: $439 · 2022: $489 · 2023: $220 · 2024: $317 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $586.55 | 2020-2024 | Veritas Vision System, Catalys System, Tecnis Iol |
| Alcon Vision LLC | $324.76 | 2019-2025 | Tryptyr, Rocklatan |
| Bausch & Lomb Americas INC. | $258.07 | 2023-2025 | Xiidra, Miebo |
| Allergan, INC. | $241.56 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $207.56 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $193.51 | 2022-2024 | Cequa |
| Mallinckrodt Hospital Products INC. | $146.10 | 2022-2025 | Acthar |
| Notal Vision, INC. | $98.42 | 2022 | |
| Abbvie INC. | $90.09 | 2023-2025 | |
| Carl Zeiss Meditec, INC. | $58.48 | 2020 | |
| Eyevance Pharmaceuticals LLC | $43.53 | 2021 | |
| Akorn Operating Company LLC | $40.63 | 2021 | |
| Harrow Eye, LLC | $39.85 | 2024-2025 | Iheezo, Vevye |
| Novartis Pharmaceuticals Corporation | $36.30 | 2019-2021 | |
| New World Medical,INC. | $35.65 | 2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $34.76 | 2023-2024 | Iyuzeh |
| Alexion Pharmaceuticals, INC. | $27.23 | 2023 | Soliris |
| Kala Pharmaceuticals, INC. | $22.80 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $19.01 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $15.89 | 2021 | |
| Staar Surgical Company | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.